Sign Out
Heart failure: Entresto is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal.
LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Pharmacology: Pharmacodynamics: Clinical efficacy and safety under Actions].
Entresto is administered in combination with other heart failure therapies (e.g. beta blockers, diuretics and mineralocorticoid antagonists) as appropriate, in place of an ACE inhibitor or ARB [see Pharmacology: Pharmacodynamics: Clinical efficacy and safety under Actions].
Hypertension: Entresto is indicated for the treatment of essential hypertension.
Entresto should not be used as a first-line drug for the treatment of hypertension because of the risk of excessive decrease in blood pressure.
